176 related articles for article (PubMed ID: 19745721)
1. Effect of artesunate on immune cells in ret-transgenic mouse melanoma model.
Ramacher M; Umansky V; Efferth T
Anticancer Drugs; 2009 Nov; 20(10):910-7. PubMed ID: 19745721
[TBL] [Abstract][Full Text] [Related]
2. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs.
Kimpfler S; Sevko A; Ring S; Falk C; Osen W; Frank K; Kato M; Mahnke K; Schadendorf D; Umansky V
J Immunol; 2009 Nov; 183(10):6330-7. PubMed ID: 19841169
[TBL] [Abstract][Full Text] [Related]
3. N-propionyl-4-S-cysteaminylphenol induces apoptosis in B16F1 cells and mediates tumor-specific T-cell immune responses in a mouse melanoma model.
Ishii-Osai Y; Yamashita T; Tamura Y; Sato N; Ito A; Honda H; Wakamatsu K; Ito S; Nakayama E; Okura M; Jimbow K
J Dermatol Sci; 2012 Jul; 67(1):51-60. PubMed ID: 22622238
[TBL] [Abstract][Full Text] [Related]
4. Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors.
Umansky V; Abschuetz O; Osen W; Ramacher M; Zhao F; Kato M; Schadendorf D
Cancer Res; 2008 Nov; 68(22):9451-8. PubMed ID: 19010920
[TBL] [Abstract][Full Text] [Related]
5. [Effects of excreted/secreted antigens of Toxoplasma gondii on CD4+ CD25+ Foxp3+ T cells and NK cells of melanoma-bearing mice].
Jiao YM; Zhang L; Ge YY; Liang YJ; Yong W
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2011 Jun; 23(3):301-6. PubMed ID: 22164498
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.
Sevko A; Sade-Feldman M; Kanterman J; Michels T; Falk CS; Umansky L; Ramacher M; Kato M; Schadendorf D; Baniyash M; Umansky V
J Invest Dermatol; 2013 Jun; 133(6):1610-9. PubMed ID: 23223128
[TBL] [Abstract][Full Text] [Related]
7. Ret transgenic mouse model of spontaneous skin melanoma: focus on regulatory T cells.
Umansky V; Sevko A
Pigment Cell Melanoma Res; 2013 Jul; 26(4):457-63. PubMed ID: 23560814
[TBL] [Abstract][Full Text] [Related]
8. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.
Hervieu A; Rébé C; Végran F; Chalmin F; Bruchard M; Vabres P; Apetoh L; Ghiringhelli F; Mignot G
J Invest Dermatol; 2013 Feb; 133(2):499-508. PubMed ID: 22951720
[TBL] [Abstract][Full Text] [Related]
9. IL-2 responsiveness of CD4 and CD8 lymphocytes: further investigations with human IL-2Rbeta transgenic mice.
Gesbert F; Moreau JL; Thèze J
Int Immunol; 2005 Aug; 17(8):1093-102. PubMed ID: 16037071
[TBL] [Abstract][Full Text] [Related]
10. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
Li T; Harada M; Tamada K; Abe K; Nomoto K
Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518
[TBL] [Abstract][Full Text] [Related]
11. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.
Machlenkin A; Goldberger O; Tirosh B; Paz A; Volovitz I; Bar-Haim E; Lee SH; Vadai E; Tzehoval E; Eisenbach L
Clin Cancer Res; 2005 Jul; 11(13):4955-61. PubMed ID: 16000595
[TBL] [Abstract][Full Text] [Related]
12. All-trans retinoic acid inhibits type 1 diabetes by T regulatory (Treg)-dependent suppression of interferon-gamma-producing T-cells without affecting Th17 cells.
Van YH; Lee WH; Ortiz S; Lee MH; Qin HJ; Liu CP
Diabetes; 2009 Jan; 58(1):146-55. PubMed ID: 18984738
[TBL] [Abstract][Full Text] [Related]
13. Skin tumor responsiveness to interleukin-2 treatment and CD8 Foxp3+ T cell expansion in an immunocompetent mouse model.
Foureau DM; McKillop IH; Jones CP; Amin A; White RL; Salo JC
Cancer Immunol Immunother; 2011 Sep; 60(9):1347-56. PubMed ID: 21638127
[TBL] [Abstract][Full Text] [Related]
14. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
Li Y; McGowan P; Hellström I; Hellström KE; Chen L
J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
[TBL] [Abstract][Full Text] [Related]
15. Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response.
Wack C; Kirst A; Becker JC; Lutz WK; Bröcker EB; Fischer WH
Cancer Immunol Immunother; 2002 Oct; 51(8):431-9. PubMed ID: 12202904
[TBL] [Abstract][Full Text] [Related]
16. Oral ingestion of Lentinula edodes mycelia extract inhibits B16 melanoma growth via mitigation of regulatory T cell-mediated immunosuppression.
Tanaka K; Ishikawa S; Matsui Y; Tamesada M; Harashima N; Harada M
Cancer Sci; 2011 Mar; 102(3):516-21. PubMed ID: 21261790
[TBL] [Abstract][Full Text] [Related]
17. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
[TBL] [Abstract][Full Text] [Related]
18. Transient activation of tumor-associated T-effector/memory cells promotes tumor eradication via NK-cell recruitment: minimal role for long-term T-cell immunity in cure of metastatic disease.
Gu T; Kilinc MO; Egilmez NK
Cancer Immunol Immunother; 2008 Jul; 57(7):997-1005. PubMed ID: 18049819
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors.
Korbelik M; Dougherty GJ
Cancer Res; 1999 Apr; 59(8):1941-6. PubMed ID: 10213504
[TBL] [Abstract][Full Text] [Related]
20. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]